Edward Maldonado

Edward Maldonado

Auto-generated profile, based on publicly available information

Edward Maldonado

University of California, San Francisco, San Francisco, California. 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
DBDavid Bond
David Bond
JSJeffrey Switchenko
Jeffrey Switchenko
DVDiego Villa
Diego Villa
KMKami Maddocks
Kami Maddocks
MCMichael C Churnetski
Michael C Churnetski
Jonathon B. CohenJonathon B. Cohen
Jonathon B. Cohen
Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

25 June 2020 in Future Science OA
Verified
Journal Article
Open access
EMEdward B Maldonado
Edward B Maldonado
SPScott Parsons
Scott Parsons
ECEmerson Y. Chen
Emerson Y. Chen
AHAlyson Haslam
Alyson Haslam
VPVinay Prasad
Vinay Prasad
Aims, patients & methods: In this retrospective review, we sought to estimate the proportion of patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recomm... Lay abstract This retrospective review sought to estimate patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recommended first-line cytotoxic chemotherap...

1 July 2024 in Cancer Research Communications
Verified
Journal Article
Open access
EMEdward Maldonado
Edward Maldonado
WRW. Kimryn Rathmell
W. Kimryn Rathmell
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
NTNaoko Takebe
Naoko Takebe
JRJordi Rodon
Jordi Rodon
RARahul Aggarwal
Rahul Aggarwal
We sought to evaluate the efficacy of WEE1 inhibitor adavosertib in patients with solid tumor malignancies (cohort A) and clear cell renal cell carcinoma (ccRCC; cohort B). NCT03284385 was a parallel cohort, Simon two-stage, phase II study of adavosertib (300 mg QDAY by mouth on days 1–5 and 8–12 of each 21-day cycle) in patients with solid tumor malignancies harboring a pathogenic SETD2 mutation. The primary endpoint was the objective response rate. Correlative assays evaluated the loss of H3K36me3 by IHC, a downstream consequence of SETD2 loss, in archival tumor tissue. Eighteen patients were enrolled (9/cohort). The median age was 60 years (range 45–74). The median duration of treatment was 1.28 months (range 0–24+). No objective responses were observed in either cohort; accrual was halted following stage 1. Minor tumor regressions were observed in 4/18 (22%) evaluable patients. Stable disease (SD) was the best overall response in 10/18 (56%) patients, including three patients with SD > 4 months. One patient with ccRCC remains on treatment for >24 months. The most common adverse events of any grade were nausea (59%), anemia (41%), diarrhea (41%), and neutropenia (41%). Nine patients (50%) experienced a Grade ≥3 adverse event. Of eight evaluable archival tissue samples, six (75%) had a loss of H3K36me3 by IHC. Adavosertib failed to exhibit objective responses in SETD2-altered ccRCC and other solid tumor malignancies although prolonged SD was observed in a subset of patients. Combination approaches may yield greater depth of tumor response. Significance: WEE1 inhibition with adavosertib monotherapy demonstrated limited clinical activity in patients with SETD2-altered solid tumors despite compelling preclinical data indicating a synthetic lethal effect, which did not translate into robust tumor regression. Loss of the H3K36me3 trimethylation mark caused by SETD2-deficiency was confirmed in the majority of evaluable tumors. A subset of patients derived clinical benefit as manifested by minor tumor regressions and prolonged SD.

23 July 2024
Verified
Other
Open access
EMEdward Maldonado
Edward Maldonado
WRW. Kimryn Rathmell
W. Kimryn Rathmell
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
NTNaoko Takebe
Naoko Takebe
JRJordi Rodon
Jordi Rodon
RARahul Aggarwal
Rahul Aggarwal
Figure 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)

23 July 2024
Verified
Other
Open access
EMEdward Maldonado
Edward Maldonado
WRW. Kimryn Rathmell
W. Kimryn Rathmell
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
NTNaoko Takebe
Naoko Takebe
JRJordi Rodon
Jordi Rodon
RARahul Aggarwal
Rahul Aggarwal
Supplementary Figure S3 shows all 8 patients with H3K36me3 IHC analysis. (A) Cohort A: Other Solid Tumor. (B) Cohort B: ccRCC. Images are at 40x power. Of note, the portal did not allow for uploading of a TIFF file alone as a "supplemental data" file, so the image included in this document is a TIFF file. We can easily provide the TIFF file if needed as well.

23 July 2024
Verified
Other
Open access
EMEdward Maldonado
Edward Maldonado
WRW. Kimryn Rathmell
W. Kimryn Rathmell
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
NTNaoko Takebe
Naoko Takebe
JRJordi Rodon
Jordi Rodon
RARahul Aggarwal
Rahul Aggarwal
Supplementary Figure S2 shows an example of no loss of H3K36me3 by IHC (A) and loss of H3K36me3 by IHC (B). Images are at 40x power. Of note, the portal did not allow for uploading of a TIFF file alone as a "supplemental data" file, so the image included in this document is a TIFF file. We can easily provide the TIFF file if needed as well.